👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views

Published 06/05/2024, 16:14
Updated 06/05/2024, 17:40
© Reuters.  Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
US500
-
TSN
-
GC
-
SI
-
IXIC
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.

The Dow traded up 0.25% to 38,772.28 while the NASDAQ rose 0.64% to 16,260.19. The S&P 500 also rose, gaining, 0.59% to 5,157.96.

Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Tech & Telecom Stocks Delivering High-Dividend Yields

Leading and Lagging Sectors

Energy shares rose by 1.5% on Monday.

In trading on Friday, consumer staples shares fell by 0.4%.

Top Headline

Tyson Foods Inc (NYSE:TSN) reported weaker-than-expected sales for its second quarter.

The company posted a second-quarter FY24 sales decline of 0.46% year-on-year to $13.072 billion, missing the analyst consensus estimate of $13.157 billion. Adjusted EPS of 62 cents beat the consensus estimate of 39 cents.

Equities Trading UP

  • Holdco Nuvo Group D.G Ltd (NASDAQ:NUVO) shares shot up 222% to $6.57.
  • Shares of Strong Global Entertainment, Inc. (NYSE:SGE) got a boost, surging 150% to $2.84 fter FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.
  • XBP Europe Holdings, Inc. (NASDAQ:XBP) shares were also up, gaining 62% to $3.4293. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty’s Passport Office.
Equities Trading DOWN

  • Lyra Therapeutics, Inc (NASDAQ:LYRA) shares dropped 90% to $0.4013 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
  • Shares of GlycoMimetics, Inc (NASDAQ:GLYC) were down 79% to $0.3831 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).
  • EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) was down, falling 39% to $11.99 after the company’s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.
Also Check This Out: Top 2 Consumer Stocks That May Plunge This Quarter

Commodities

In commodity news, oil traded up 0.7% to $78.63 while gold traded up 0.9% at $2,329.90.

Silver traded up 2.9% to $27.45 on Monday, while copper rose 1.3% to $4.6165.

Euro zone

European shares were higher today. The eurozone's STOXX 600 rose 0.5%, Germany's DAX rose 0.9% and France's CAC 40 gained 0.4%. Spain's IBEX 35 Index rose 0.5%, while London's FTSE 100 rose 0.5%.

Asia Pacific Markets

Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&P BSE Sensex rising 0.02%.

Economics

No major economic reports will be released today.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.